Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Yttrium-90 besilesomab - Telix Pharmaceuticals

Next Previous
X
Search
Drug Profile

Yttrium-90 besilesomab - Telix Pharmaceuticals

Alternative Names: 90Y-besilesomab; TLX 66; Y-90-anti-CD66 - Telix Pharmaceuticals; Yttrium-90 labelled anti-CD66 monoclonal antibody - Telix Pharmaceuticals

Latest Information Update: 05 Apr 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telix Pharmaceuticals
  • Developer Telix Pharmaceuticals; University of Southampton
  • Class Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid light-chain amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Amyloid light-chain amyloidosis

Most Recent Events

  • 04 Apr 2022 Great Ormond Street Hospital plans a phase-II trial for leukemia (In children, In adolescents) in United Kingdom in April 2022 (NCT04856215)
  • 28 Mar 2022 Yttrium-90 besilesomab receives Orphan Drug status for Amyloid light-chain amyloidosis in European Union, prior to March 2022
  • 28 Mar 2022 Yttrium-90 besilesomab receives Orphan Drug status for Amyloid light-chain amyloidosis in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top